Posted On: January 11, 2008
A UK based consortium, which includes AvantiCell Science (Ayr) and Fleet Bioprocessing (Reading), will participate in the three year project to discover new anti-cancer compounds derived from the microbial resource of the sea. The programme aims to demonstrate the potential of potent marine based bio-actives which through conjugation to monoclonal antibodies/nanoparticles could lead to a new generation of therapeutic candidates. Using proprietary technology Aquapharm is able to grow and elicit novel molecules from marine microbes which can then be screened and chemically conjugated so as to provide targeted anti-tumour activity and specificity. Aquapharm Biodiscovery and its partners, AvantiCell Science and Fleet Bioprocessing aim to develop at least 2 novel anti-cancer conjugates with demonstrated therapeutic value based upon clinical in-vitro and in-vivo efficacy over the next three years.
More Information
